Analysis of the Enteric Nervous System Using Colonic Biopsies (ColoBioParker)
Primary Purpose
Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
colonoscopy or rectosigmoidoscopy
Sponsored by
About this trial
This is an interventional diagnostic trial for Parkinson's Disease focused on measuring biopsies, enteric nervous system, biomarker
Eligibility Criteria
Inclusion Criteria:
Patients
- Patients aged 50-80 year old, both genders
- Parkinson's disease patients
- Multiple system atrophy patients
- Progressive supranuclear palsy patients
- Controls: patient at risk of colic cancer for whom a colonoscopy is required
- Patients who signed the informed consent
Controls
- Patients aged 50 to 80 year-old for whom a rectosigmoidoscopy or a colonoscopy is required for colorectal screening
- Patients who signed the informed consent
- Health care beneficiary
Exclusion Criteria:
Patients
- Colonic disorder (except non-complicated diverticular disease)
- Other neurological disorder than parkinsonism
- Patients treated with either platelet antiaggregants, anticoagulants or with a known coagulation disorder
- Patients with a cognitive impairment that preclude them from understanding the informed consent
- Patients placed under legal guardianship
Controls
- Neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease or other dementia, amyotrophic lateral sclerosis...
- Functional bowel disorder such as irritable bowel syndrome
- Patients with a cognitive impairment that preclude them from understanding the informed consent
Sites / Locations
- Nantes University Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Colonic biopsies
Arm Description
Colonic biopsies obtained during the course of colonoscopy or rectosigmoidoscopy
Outcomes
Primary Outcome Measures
Presence of alpha-synuclein aggregates in colonic biopsies using immunohistochemistry
Colonic biopsies are obtained during the course of colonoscopy or rectosigmoidoscopy.
Secondary Outcome Measures
Presence of alpha-synuclein aggregates in colonic biopsies using 2D electrophoresis
Colonic biopsies are obtained during the course of colonoscopy or rectosigmoidoscopy.
Full Information
NCT ID
NCT01353183
First Posted
January 31, 2011
Last Updated
September 18, 2013
Sponsor
Nantes University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT01353183
Brief Title
Analysis of the Enteric Nervous System Using Colonic Biopsies
Acronym
ColoBioParker
Official Title
Analysis of the Enteric Nervous System Using Colonic Biopsies: a Useful Biomarker for the Differential Diagnosis of Parkinsonian Syndromes?
Study Type
Interventional
2. Study Status
Record Verification Date
September 2013
Overall Recruitment Status
Completed
Study Start Date
November 2010 (undefined)
Primary Completion Date
November 2012 (Actual)
Study Completion Date
November 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Nantes University Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of this project is to develop an original biomarker for Parkinson's disease (PD) and other parkinsonian syndromes (multiple system atrophy and progressive supranuclear palsy) based upon the detection of pathological alpha-synuclein species in routine colonoscopic biopsies.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
Keywords
biopsies, enteric nervous system, biomarker
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
34 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Colonic biopsies
Arm Type
Experimental
Arm Description
Colonic biopsies obtained during the course of colonoscopy or rectosigmoidoscopy
Intervention Type
Procedure
Intervention Name(s)
colonoscopy or rectosigmoidoscopy
Intervention Description
Usual procedure
Primary Outcome Measure Information:
Title
Presence of alpha-synuclein aggregates in colonic biopsies using immunohistochemistry
Description
Colonic biopsies are obtained during the course of colonoscopy or rectosigmoidoscopy.
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Presence of alpha-synuclein aggregates in colonic biopsies using 2D electrophoresis
Description
Colonic biopsies are obtained during the course of colonoscopy or rectosigmoidoscopy.
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients
Patients aged 50-80 year old, both genders
Parkinson's disease patients
Multiple system atrophy patients
Progressive supranuclear palsy patients
Controls: patient at risk of colic cancer for whom a colonoscopy is required
Patients who signed the informed consent
Controls
Patients aged 50 to 80 year-old for whom a rectosigmoidoscopy or a colonoscopy is required for colorectal screening
Patients who signed the informed consent
Health care beneficiary
Exclusion Criteria:
Patients
Colonic disorder (except non-complicated diverticular disease)
Other neurological disorder than parkinsonism
Patients treated with either platelet antiaggregants, anticoagulants or with a known coagulation disorder
Patients with a cognitive impairment that preclude them from understanding the informed consent
Patients placed under legal guardianship
Controls
Neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease or other dementia, amyotrophic lateral sclerosis...
Functional bowel disorder such as irritable bowel syndrome
Patients with a cognitive impairment that preclude them from understanding the informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
DERKINDEREN Pascal, Professor
Organizational Affiliation
Nantes University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Nantes University Hospital
City
Nantes
ZIP/Postal Code
44093
Country
France
12. IPD Sharing Statement
Learn more about this trial
Analysis of the Enteric Nervous System Using Colonic Biopsies
We'll reach out to this number within 24 hrs